AIMS: BG00010 is a protein in the glial cell line-derived neurotrophic factor (GDNF) family. It is a selective ligand for the GDNF family receptor alpha-3 (GFRα3) co-receptor that normalizes cellular changes resulting from damage or disease, and potentially alleviates neuropathic pain. The main objectives of this study were to evaluate the pharmacokinetic and safety profiles and to determine the effects on pain of ascending doses of intravenous injections of BG00010 in patients with sciatica. METHODS: This was a randomized, blinded, placebo-controlled multiple-dose study in subjects with sciatica. In Part I (16 patients), four IV dose levels were examined (50, 150, 400, 800 μg kg(-1) ) and in Part II (12 patients), three dose levels were examined (400, 600 and 1200 μg kg(-1) ). Safety and efficacy assessments were used as endpoints. RESULTS: The BG00010 concentration-time data indicated relatively low inter-patient variability and there was a dose-dependent (not dose-proportional) increase in serum exposure from 150 to 1200 μg kg(-1) . The effective half-life was between 40 and 60 h. The most frequently occurring adverse events (AEs) reported by patients receiving BG00010 were headache (67-83%), feeling hot (50-100%), and pruritus (42-67%). Most AEs were mild; no serious AEs or AEs leading to discontinuation occurred. Higher dose regimens of BG00010 resulted in greater pain reduction than placebo or lower dose regimens, although a clear dose-response relationship was not seen. CONCLUSIONS: The pharmacokinetic profile of BG00010 was characterized by low intra-patient variability. These data from a small sample suggest that BG00010 may have a benefit for patients with sciatica.
RCT Entities:
AIMS: BG00010 is a protein in the glial cell line-derived neurotrophic factor (GDNF) family. It is a selective ligand for the GDNF family receptor alpha-3 (GFRα3) co-receptor that normalizes cellular changes resulting from damage or disease, and potentially alleviates neuropathic pain. The main objectives of this study were to evaluate the pharmacokinetic and safety profiles and to determine the effects on pain of ascending doses of intravenous injections of BG00010 in patients with sciatica. METHODS: This was a randomized, blinded, placebo-controlled multiple-dose study in subjects with sciatica. In Part I (16 patients), four IV dose levels were examined (50, 150, 400, 800 μg kg(-1) ) and in Part II (12 patients), three dose levels were examined (400, 600 and 1200 μg kg(-1) ). Safety and efficacy assessments were used as endpoints. RESULTS: The BG00010 concentration-time data indicated relatively low inter-patient variability and there was a dose-dependent (not dose-proportional) increase in serum exposure from 150 to 1200 μg kg(-1) . The effective half-life was between 40 and 60 h. The most frequently occurring adverse events (AEs) reported by patients receiving BG00010 were headache (67-83%), feeling hot (50-100%), and pruritus (42-67%). Most AEs were mild; no serious AEs or AEs leading to discontinuation occurred. Higher dose regimens of BG00010 resulted in greater pain reduction than placebo or lower dose regimens, although a clear dose-response relationship was not seen. CONCLUSIONS: The pharmacokinetic profile of BG00010 was characterized by low intra-patient variability. These data from a small sample suggest that BG00010 may have a benefit for patients with sciatica.
Authors: Luis R Gardell; Ruizhong Wang; Chris Ehrenfels; Michael H Ossipov; Anthony J Rossomando; Stephan Miller; Carolyn Buckley; Amber K Cai; Albert Tse; Susan F Foley; BangJian Gong; Lee Walus; Paul Carmillo; Dane Worley; Carol Huang; Thomas Engber; Blake Pepinsky; Richard L Cate; Todd W Vanderah; Josephine Lai; Dinah W Y Sah; Frank Porreca Journal: Nat Med Date: 2003-10-05 Impact factor: 53.440
Authors: Ruizhong Wang; Tamara King; Michael H Ossipov; Anthony J Rossomando; Todd W Vanderah; Pamela Harvey; Peter Cariani; Eric Frank; Dinah W Y Sah; Frank Porreca Journal: Nat Neurosci Date: 2008-03-23 Impact factor: 24.884
Authors: R H Baloh; M G Tansey; P A Lampe; T J Fahrner; H Enomoto; K S Simburger; M L Leitner; T Araki; E M Johnson; J Milbrandt Journal: Neuron Date: 1998-12 Impact factor: 17.173
Authors: Abdelilah El Barzouhi; Carmen L A M Vleggeert-Lankamp; Geert J Lycklama À Nijeholt; Bas F Van der Kallen; Wilbert B van den Hout; Annemieke J H Verwoerd; Bart W Koes; Wilco C Peul Journal: PLoS One Date: 2013-07-10 Impact factor: 3.240
Authors: Yulia A Sidorova; Maxim M Bespalov; Agnes W Wong; Oleg Kambur; Viljami Jokinen; Tuomas O Lilius; Ilida Suleymanova; Gunnar Karelson; Pekka V Rauhala; Mati Karelson; Peregrine B Osborne; Janet R Keast; Eija A Kalso; Mart Saarma Journal: Front Pharmacol Date: 2017-06-21 Impact factor: 5.810
Authors: Richelle Sopko; Joshua W Mugford; Andreas Lehmann; Renée I Shapiro; Mia Rushe; Abhishek Kulkarni; Joseph Worrall; Joseph Amatucci; Dingyi Wen; Nels E Pederson; Brenda K Minesinger; Joseph W Arndt; Blake Pepinsky Journal: Protein Eng Des Sel Date: 2017-05-01 Impact factor: 1.650
Authors: Mirolyuba Ilieva; Janne Nielsen; Irina Korshunova; Kamil Gotfryd; Elisabeth Bock; Stanislava Pankratova; Tanja Maria Michel Journal: Front Mol Neurosci Date: 2019-02-22 Impact factor: 5.639